Adlai Nortye Ltd. American Depositary Shares (ANL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $15.75 (+3.08%), Market cap $0.87B, 52-week low–high $0.88 ~ $16.60.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed
Financial statements, price targets, institutional (13F) holdings and related news for Adlai Nortye Ltd. American Depositary Shares are updated in real time on BlackAll Trade.
Adlai Nortye Ltd. American Depositary Shares trades at $15.75 (+3.08%). Real-time quotes and charts are available on BlackAll Trade.
Adlai Nortye Ltd. American Depositary Shares has a market cap of about $0.87B.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 a